A systematic literature review was conducted using Embase, MEDLINE, MEDLINE-In Process and Cochrane databases to identify the randomised/non-randomised controlled trials (RCTs/non-RCTs) and real-world observational studies of CAPS, HIDS/MKD and TRAPS published as full-texts (January 2000-September 2017) or conference abstracts (January 2014-September 2017). Studies with data for ≥1 biologic were included. Studies with <5 patients were excluded.
Of the 3 342 retrieved publications, 72 studies were included (CAPS, n=43; HIDS/MKD, n=9; TRAPS, n=7; studies with ≥2 cohorts, n=13). Most studies were full-text (n=56), published after 2010 (n=56) and real-world observational studies (n=58). Among included studies, four were RCTs (canakinumab, n=2 (CAPS, n=1; HIDS/MKD and TRAPS, n=1); rilonacept, n=1 (in CAPS); simvastatin, n=1 (in HIDS/MKD)). Canakinumab and anakinra were the most commonly used therapies for CAPS and HIDS/MKD, whereas etanercept, canakinumab and anakinra were the most common for TRAPS. The available evidence suggested the efficacy or effectiveness of canakinumab and anakinra in CAPS, HIDS/MKD and TRAPS, and of etanercept in TRAPS; asingle RCT demonstrated the efficacy of rilonacept in CAPS.
Canakinumab, anakinra, etanercept and rilonacept were reported to be well tolerated; however, injection-site reactions were observed frequently with anakinra, rilonacept and etanercept. Data on the use of tocilizumab, infliximab and adalimumab in these conditions were limited; thus, further research is warranted.
使用Embase进行了系统的文献综述,MEDLINE,MEDLINE-InProcess和Cochrane数据库,用于确定CAPS的随机/非随机对照试验(RCT/非RCT)和真实世界观察性研究,HIDS/MKD和TRAPS以全文(2000年1月至2017年9月)或会议摘要(2014年1月至2017年9月)发布。包括≥1个生物学数据的研究。排除<5名患者的研究。
在检索到的3342份出版物中,包括72项研究(CAPS,n=43;HIDS/MKD,n=9;陷阱,n=7;具有≥2个队列的研究,n=13)。大多数研究是全文(n=56),2010年后发表的(n=56)和真实世界的观察研究(n=58)。在纳入的研究中,四个是随机对照试验(canakinumab,n=2(CAPS,n=1;HIDS/MKD和TRAPS,n=1);rilonacept,n=1(CAPS);辛伐他汀,n=1(在HIDS/MKD中)。Canakinumab和anakinra是CAPS和HIDS/MKD最常用的疗法,而依那西普,canakinumab和anakinra是TRAPS最常见的.现有证据表明canakinumab和anakinra在CAPS中的疗效或有效性,HIDS/MKD和陷阱,和etanercept在TRAPS中的应用;asingleRCT证明了利洛纳康在CAPS中的疗效。
Canakinumab,anakinra,据报道,依那西普和利洛纳西普的耐受性良好;然而,经常观察到Anakinra的注射部位反应,rilonacept和etanercept。使用托珠单抗的数据,英夫利昔单抗和阿达木单抗在这些情况下是有限的;因此,需要进一步的研究。